shareholder proposal · 2024
Trinity Health at AbbVie, Eli Lilly, Gilead Sciences, Johnson & Johnson, Merck & Co., Pfizer
Establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents, the report prepared at reasonable cost, omitting confidential and proprietary information, and made public.
What happened
Result: Not approved where it reached a vote. AbbVie, 3 May 2024: 315,426,248 for, 941,651,498 against, 17,953,817 abstaining and 245,929,517 broker non-votes. Eli Lilly, 6 May 2024: 68,370,561 for, 699,538,270 against, 6,506,288 abstaining and 82,256,109 broker non-votes. At the other four companies it did not reach a vote.
Not approved at Eli Lilly, the one company where a vote was certified; not among the items voted at Johnson & Johnson; and absent from the 2024 proxy statements of Gilead, Merck and Pfizer.
Who is involved
- Trinity Health filer
- Bon Secours Mercy Health, Inc. co-filer
- The Sisters of the Order of St. Dominic (Grand Rapids) co-filer
- NEI Investments co-filer
- Northwest Women Religious Investment Trust (Sisters of Saint Joseph of Peace) co-filer
- Providence St. Joseph Health co-filer
- Missionary Oblates of Mary Immaculate co-filer
- AbbVie company
- Eli Lilly company
- Gilead Sciences company
- Johnson & Johnson company
- Merck & Co. Animal Health company
- Pfizer Inc. company
What this campaign is about
- Cap U.S. drug prices based on prices in other developed countries Pivotal · Common Ground of the American People